The rule that's broken is that peek opportunities must be set up in advance of the trial as part of the protocol. You can't later, mid-trial, suddenly get curious and peek.
Changing the regulatory status of a trial, increasing n, or changing endpoints does not interfere with the conduct of the trial. You need to protect the integrity of the underlying data at all costs. Peeking raises data integrity issues.
It would be nice if an early "peek" guaranteed a higher share price "peak", wouldn't it? Of course, there would be no guarantee of that but maybe this will help a bit in when to use "peek" and when to use "peak"...hehe
News 
Market Data 
Discover 
AI
